Qiagen's $1.6B Bid for Digene Passes Federal Waiting Period | GenomeWeb
NEW YORK (GenomeWeb News) — Qiagen today said that federal regulators have cleared its planned acquisition of Digene.
 
The company said the Hart-Scott-Rodino antitrust deadline passed on midnight yesterday without a hitch, enabling the shop to buy Digene for $1.6 billion.
 
The deal is subject to the tender of a majority of Digene's common stock on a fully diluted basis before 11:59 p.m. EST on July 20, unless the offer is extended, as well as approval by Qiagen’s shareholders, among other conditions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.